Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

NCT03176771 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Tardive Dyskinesia

Interventions

DRUG: MT-5199
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation